Drug interactions
Glecaprevir / pibrentasvir + Rimegepant
Severity: Moderate
Glecaprevir / pibrentasvir and Rimegepant: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Glecaprevir and pibrentasvir inhibit intestinal P-glycoprotein and may raise rimegepant exposure. Higher levels could increase the likelihood of rimegepant adverse effects such as nausea and hypersensitivity reactions.
What this interaction means in plain words
Glecaprevir / pibrentasvir and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Inhibition of P-glycoprotein efflux of rimegepant, which increases its absorption and systemic exposure.
What to do
Rimegepant labeling advises avoiding a repeat dose within 48 hours when given with P-gp inhibitors. Counsel the patient accordingly and monitor tolerability.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glecaprevir / pibrentasvir and Rimegepant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rimegepant
Frequently asked questions
Can I take Glecaprevir / pibrentasvir with Rimegepant?
MediHelp rates the interaction as moderate. Glecaprevir / pibrentasvir and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Glecaprevir and pibrentasvir inhibit intestinal P-glycoprotein and may raise rimegepant exposure. Higher levels could increase the likelihood of rimegepant adverse effects such as nausea and hypersensitivity reactions.
How serious is the interaction between Glecaprevir / pibrentasvir and Rimegepant?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Rimegepant labeling advises avoiding a repeat dose within 48 hours when given with P-gp inhibitors. Counsel the patient accordingly and monitor tolerability.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
